Excerpts from EF Hutton Oct 1 report:
"Was the Trial a Failure or a Success? The initial data analysis showed that the
primary effectiveness endpoint in the overall patient population that underwent
different cardiac surgeries was unmet. However, the pre-specified subpopulation of
patients undergoing isolated coronary artery bypass graft (CABG) surgery, which
accounted for 90% of patients enrolled in the trial, showed evidence of reduced
bleeding complications, including serious bleeding events"
Also disclosed new info about manufacturing problem:
. "A planned slowdown in production to rebalance inventory, combined with a shortterm manufacturing issue, led to fewer CytoSorb devices produced and lower product gross margins of 50% to 60%, down from 71% in Q3 2023"
Has Management disclosed this to shareholders????
Market Data 
Markets 
